Panbela announces paces s0820 phase iii trial passes pre-planned futility analysis

Minneapolis, june 28, 2023 (globe newswire) -- panbela therapeutics, inc . (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the swog cancer research network's paces s0820 phase iii trial passed a single planned futility analysis and will continue. the trial entitled: “a double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-iii colon or rectal cancer, phase iii - preventing adenomas of the colon with eflornithine and sulindac (paces)” is designed to evaluate the combination of eflornithine and sulindac in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for stages 0 through iii colon or rectal cancer.
PBLA Ratings Summary
PBLA Quant Ranking